SG11201909218RA - Antibodies binding to steap-1 - Google Patents

Antibodies binding to steap-1

Info

Publication number
SG11201909218RA
SG11201909218RA SG11201909218RA SG11201909218RA SG 11201909218R A SG11201909218R A SG 11201909218RA SG 11201909218R A SG11201909218R A SG 11201909218RA SG 11201909218R A SG11201909218R A SG 11201909218RA
Authority
SG
Singapore
Prior art keywords
roche
international
antibodies
wagistrasse
penzberg
Prior art date
Application number
Inventor
Thomas Hofer
Maximiliane Koenig
Ekkehard Moessner
Jens Niewoehner
Tina Weinzierl
Laurent Lariviere
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of SG11201909218RA publication Critical patent/SG11201909218RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pregnancy & Childbirth (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 11 October 2018 (11.10.2018) WIPO I PCT D IV °nolo iflo oimIE (10) International Publication Number WO 2018/184966 Al (51) International Patent Classification: C07K 16/30 (2006.01) A61K 39/00 (2006.01) A61K 47/68 (2017.01) (21) International Application Number: PCT/EP2018/058043 (22) International Filing Date: 29 March 2018 (29.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 17164466.9 03 April 2017 (03.04.2017) EP (71) Applicant (for all designated States except US): F. HOFF- MANN-LA ROCHE AG [CH/CH]; Grenzacherstrasse 124, 4070 Basel (CH). (71) Applicant (for US only): HOFFMANN-LA ROCHE INC. [US/US]; Overlook at Great Notch, 150 Clove Road, 8th Floor, Suite 8 - Legal Department, Little Falls, New Jer- sey 07424 (US). (72) Inventors: HOFER, Thomas; c/o Roche Glycart AG, Wagistrasse 18, 8952 Schlieren (CH). KOENIG, Maximil- iane; c/o Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg (DE). MOESSNER, Ekkehard; c/o Roche Gly- cart AG, Wagistrasse 18, 8952 Schlieren (CH). NIE- WOEHNER, Jens; c/o Roche Diagnostics GmbH, Non- nenwald 2, 82377 Penzberg (DE). WEINZIERL, Tina; c/ o Roche Glycart AG, Wagistrasse 18, 8952 Schlieren (CH). LARIVIERE, Laurent; c/o Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg (DE). TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — of inventorship (Rule 4.17(iv)) Published: — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a)) 1-1 71 00 - 1-1 00 1-1 O (74) Agent: CUENI, Leah; Grenzacherstrasse 124, 4070 Basel (CH). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (54) Title: ANTIBODIES BINDING TO STEAP-1 (57) : The present invention generally relates to antibodies that bind to STEAP-1, including bispecific antigen binding mole- cules e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.
SG11201909218R 2017-04-03 2018-03-29 Antibodies binding to steap-1 SG11201909218RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17164466 2017-04-03
PCT/EP2018/058043 WO2018184966A1 (en) 2017-04-03 2018-03-29 Antibodies binding to steap-1

Publications (1)

Publication Number Publication Date
SG11201909218RA true SG11201909218RA (en) 2019-11-28

Family

ID=58489188

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201909218R SG11201909218RA (en) 2017-04-03 2018-03-29 Antibodies binding to steap-1

Country Status (20)

Country Link
US (3) US11180571B2 (en)
EP (1) EP3606963B1 (en)
JP (1) JP7247101B2 (en)
KR (1) KR102667951B1 (en)
CN (1) CN110494452B (en)
AU (1) AU2018247767A1 (en)
BR (1) BR112019018767A2 (en)
CA (1) CA3055132A1 (en)
CL (1) CL2019002735A1 (en)
CO (1) CO2019010164A2 (en)
CR (1) CR20190430A (en)
ES (1) ES2955852T3 (en)
IL (1) IL269394A (en)
MA (1) MA49289A (en)
MX (1) MX2019011769A (en)
PE (1) PE20200010A1 (en)
PH (1) PH12019502274A1 (en)
RU (1) RU2019134462A (en)
SG (1) SG11201909218RA (en)
WO (1) WO2018184966A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA53094A (en) 2018-07-02 2021-05-12 Amgen Inc ANTI-STEAP1 ANTIGEN BINDING PROTEIN
CN112955240B (en) * 2018-10-25 2022-09-16 豪夫迈·罗氏有限公司 Modification of antibody FcRn binding
IL315265A (en) * 2022-03-03 2024-10-01 Pfizer Inc Multispecific antibodies and uses thereof
GB202208119D0 (en) 2022-06-01 2022-07-13 Univ Oslo Hf Anti-steap1 car

Family Cites Families (181)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US830930A (en) 1905-11-22 1906-09-11 E & T Fairbanks & Co Weighing-scale.
CH605550A5 (en) 1972-06-08 1978-09-29 Research Corp
IT1156905B (en) 1977-04-18 1987-02-04 Hitachi Metals Ltd ORNAMENT ITEM SUITABLE TO BE FIXED USING A PERMANENT MAGNET
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5597531A (en) 1985-10-04 1997-01-28 Immunivest Corporation Resuspendable coated magnetic particles and stable magnetic particle suspensions
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
FR2601675B1 (en) 1986-07-17 1988-09-23 Rhone Poulenc Sante TAXOL DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE68913658T3 (en) 1988-11-11 2005-07-21 Stratagene, La Jolla Cloning of immunoglobulin sequences from the variable domains
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
US6020145A (en) 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
US5698271A (en) 1989-08-22 1997-12-16 Immunivest Corporation Methods for the manufacture of magnetically responsive particles
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DK0564531T3 (en) 1990-12-03 1998-09-28 Genentech Inc Enrichment procedure for variant proteins with altered binding properties
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
WO1992022653A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
ES2136092T3 (en) 1991-09-23 1999-11-16 Medical Res Council PROCEDURES FOR THE PRODUCTION OF HUMANIZED ANTIBODIES.
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
US5489525A (en) 1992-10-08 1996-02-06 The United States Of America As Represented By The Department Of Health And Human Services Monoclonal antibodies to prostate cells
DE69329503T2 (en) 1992-11-13 2001-05-03 Idec Pharma Corp Therapeutic use of chimeric and labeled antibodies directed against a differentiation antigen, the expression of which is restricted to human B lymphocyte, for the treatment of B cell lymphoma
EP0679716A4 (en) 1993-11-12 1999-06-09 Kenichi Matsubara Gene signature.
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US5859045A (en) 1996-05-08 1999-01-12 Novo Nordisk A/S Novo Alle Crystalline -! 3R 4R-trans-7 methoxy 2,2-dimethyl1-3-phenyl 1-4 4-12 pyrrolidin-1 -Y1!ethoxyl 1!chromane hydrogen fumarate
US5824504A (en) 1996-09-26 1998-10-20 Elshourbagy; Nabil A. Human 7-transmembrane receptor and DNA
WO1998018489A1 (en) 1996-10-30 1998-05-07 The Uab Research Foundation Enhancement of tumor cell chemosensitivity and radiosensitivity using single chain intracellular antibodies
US6262245B1 (en) 1997-02-25 2001-07-17 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US6800746B2 (en) 1997-02-25 2004-10-05 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
WO1998037418A2 (en) 1997-02-25 1998-08-27 Corixa Corporation Compounds for immunodiagnosis of prostate cancer and methods for their use
WO2002102994A2 (en) 2001-03-21 2002-12-27 Human Genome Sciences, Inc. Human secreted proteins
IL132560A0 (en) 1997-05-02 2001-03-19 Genentech Inc A method for making multispecific antibodies having heteromultimeric and common components
AU7592998A (en) 1997-05-23 1998-12-11 Biogen, Inc. Modulators of tissue regeneration
AU757627B2 (en) 1997-06-24 2003-02-27 Genentech Inc. Methods and compositions for galactosylated glycoproteins
CA2296287A1 (en) 1997-08-01 1999-02-11 Genset 5' ests for secreted proteins expressed in prostate
EP1000146B1 (en) 1997-08-01 2006-08-30 Serono Genetics Institute S.A. 5'ESTs FOR NON TISSUE SPECIFIC SECRETED PROTEINS
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
JPH1164691A (en) 1997-08-25 1999-03-05 Furukawa Electric Co Ltd:The Noncut clip
US20030060612A1 (en) 1997-10-28 2003-03-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
ATE419009T1 (en) 1997-10-31 2009-01-15 Genentech Inc METHODS AND COMPOSITIONS CONSISTING OF GLYCOPROTEIN GLYCOFORMS
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
US6365362B1 (en) 1998-02-12 2002-04-02 Immunivest Corporation Methods and reagents for the rapid and efficient isolation of circulating cancer cells
DK2180007T4 (en) 1998-04-20 2017-11-27 Roche Glycart Ag Glycosylation technique for antibodies to enhance antibody-dependent cell cytotoxicity
US20030064397A1 (en) 1998-05-22 2003-04-03 Incyte Genomics, Inc. Transmembrane protein differentially expressed in prostate and lung tumors
US6048970A (en) 1998-05-22 2000-04-11 Incyte Pharmaceuticals, Inc. Prostate growth-associated membrane proteins
ATE437947T1 (en) 1998-06-01 2009-08-15 Agensys Inc SERPENT TRANS MEMBRANE ANTIGENS EXPRESSED IN HUMAN CANCER AND THEIR USES
US6833438B1 (en) 1999-06-01 2004-12-21 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US20030149531A1 (en) 2000-12-06 2003-08-07 Hubert Rene S. Serpentine transmembrane antigens expressed in human cancers and uses thereof
KR20070112860A (en) 1998-07-14 2007-11-27 코릭사 코포레이션 An isolated immnogenic portion of the prostate tumor protein and methods for diagnosis of prostate cancer using the same
CA2362423A1 (en) 1998-12-17 2000-06-22 Human Genome Sciences, Inc. 47 human secreted proteins
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
CA2372053C (en) 1999-04-28 2008-09-02 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting vegf
JP2003502061A (en) 1999-06-11 2003-01-21 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド 48 human secreted proteins
EP1206543A2 (en) 1999-08-17 2002-05-22 Incyte Genomics, Inc. Membrane associated proteins
PT1222292E (en) 1999-10-04 2005-11-30 Medicago Inc METHOD FOR REGULATING THE TRANSCRIPTION OF EXOGENEOUS GENES IN THE PRESENCE OF NITROGEN
WO2001025272A2 (en) 1999-10-04 2001-04-12 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
UA74798C2 (en) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Method for treating cancer in mammals using polypeptide interfering with interaction between april and its receptors
EP1230364A2 (en) 1999-11-12 2002-08-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
PT1244705E (en) 1999-12-06 2010-05-04 Agensys Inc Serpentine transmembrane antigens expressed in human prostate cancers and uses thereof
JP2003516755A (en) 1999-12-15 2003-05-20 ジェネンテック・インコーポレーテッド Shotgun scanning, a combined method for mapping functional protein epitopes
HUP0203968A3 (en) 2000-01-14 2004-09-28 Corixa Corp Seattle Compositions and methods for the therapy and diagnosis of prostate cancer
WO2001057190A2 (en) 2000-02-03 2001-08-09 Hyseq, Inc. Novel nucleic acids and polypeptides
GB2373500B (en) 2000-02-04 2004-12-15 Aeomica Inc Methods and apparatus for predicting, confirming, and displaying functional information derived from genomic sequence
WO2001060860A2 (en) 2000-02-17 2001-08-23 Millennium Predictive Medicine, Inc. Genes differentially expressed in human prostate cancer and their use
AU2001249411B2 (en) 2000-03-24 2007-02-15 Fahri Saatcioglu Novel prostate-specific or testis-specific nucleic acid molecules, polypeptides,and diagnostic and therapeutic methods
AU2001249549A1 (en) 2000-03-27 2001-10-08 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
EP1272647B1 (en) 2000-04-11 2014-11-12 Genentech, Inc. Multivalent antibodies and uses therefor
CA2411601A1 (en) 2000-06-05 2001-12-13 Avalon Pharmaceuticals Cancer gene determination and therapeutic screening using signature gene sets
JP2004512022A (en) 2000-06-09 2004-04-22 コリクサ　コーポレイション Compositions and methods for treatment and diagnosis of colon cancer
WO2002010449A2 (en) 2000-07-28 2002-02-07 Compugen Inc. Oligonucleotide library for detecting rna transcripts and splice variants that populate a transcriptome
EP1445318A2 (en) 2000-08-24 2004-08-11 Genetech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2002030268A2 (en) 2000-10-13 2002-04-18 Eos Biotechnology, Inc. Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
EP1341804A4 (en) 2000-11-17 2005-08-24 Nuvelo Inc Novel nucleic acids and polypeptides
PT1354034E (en) 2000-11-30 2008-02-28 Medarex Inc Transgenic transchromosomal rodents for making human antibodies
WO2002057303A2 (en) 2001-01-12 2002-07-25 Hybrigenics Protein-protein interactions between shigella flexneri polypeptides and mammalian polypeptides
US20030108963A1 (en) 2001-07-25 2003-06-12 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kit, and methods for identification, assessment, prevention and therapy of prostate cancer
NZ592087A (en) 2001-08-03 2012-11-30 Roche Glycart Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
WO2003022995A2 (en) 2001-09-06 2003-03-20 Agensys, Inc. Nucleic acid and corresponding protein entitled steap-1 useful in treatment and detection of cancer
US7494646B2 (en) 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
WO2003022955A1 (en) 2001-09-11 2003-03-20 Nessdisplay Co., Ltd. Organic electroluminescent device having a polyimide hole transport layer
US7091186B2 (en) 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
AU2002337935B2 (en) 2001-10-25 2008-05-01 Genentech, Inc. Glycoprotein compositions
EP1308459A3 (en) 2001-11-05 2003-07-09 Research Association for Biotechnology Full-length cDNA sequences
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
ES2362419T3 (en) 2002-04-09 2011-07-05 Kyowa Hakko Kirin Co., Ltd. CELLS WITH DEPRESSION OR DELETION OF THE ACTIVITY OF THE PROTEIN THAT PARTICIPATES IN THE TRANSPORT OF GDP-FUCOSA.
WO2003085107A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cells with modified genome
EP1498491A4 (en) 2002-04-09 2006-12-13 Kyowa Hakko Kogyo Kk METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO Fc GAMMA RECEPTOR IIIa
JP4832719B2 (en) 2002-04-09 2011-12-07 協和発酵キリン株式会社 Medicine containing antibody composition for FcγRIIIa polymorphism patients
EP1498490A4 (en) 2002-04-09 2006-11-29 Kyowa Hakko Kogyo Kk Process for producing antibody composition
CA2488441C (en) 2002-06-03 2015-01-27 Genentech, Inc. Synthetic antibody phage libraries
US7659241B2 (en) 2002-07-31 2010-02-09 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
PT1572744E (en) 2002-12-16 2010-09-07 Genentech Inc Immunoglobulin variants and uses thereof
WO2004065416A2 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
KR101292000B1 (en) 2003-01-22 2013-08-01 로슈 글리카트 아게 FUSION CONSTRUCTS AND USE OF SAME TO PRODUCE ANTIBODIES WITH INCREASED Fc RECEPTOR BINDING AFFINITY AND EFFECTOR FUNCTION
DE602004030220D1 (en) 2003-02-27 2011-01-05 Veridex Llc CIRCULATING TUMOR CELLS (CTCs): EARLY ASSESSMENT OF TIME-TO-PROGRESSION, SURVIVAL AND RESPONSE TO THERAPY IN PATIENTS WITH METASTASED CANCER
AU2004242846A1 (en) 2003-05-31 2004-12-09 Micromet Ag Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders
BR122018071808B8 (en) 2003-11-06 2020-06-30 Seattle Genetics Inc conjugate
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
JP5128935B2 (en) 2004-03-31 2013-01-23 ジェネンテック， インコーポレイテッド Humanized anti-TGF-β antibody
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
EP2360186B1 (en) 2004-04-13 2017-08-30 F. Hoffmann-La Roche AG Anti-P-selectin antibodies
NZ550816A (en) 2004-04-22 2009-12-24 Agensys Inc Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
TWI380996B (en) 2004-09-17 2013-01-01 Hoffmann La Roche Anti-ox40l antibodies
CA2580141C (en) 2004-09-23 2013-12-10 Genentech, Inc. Cysteine engineered antibodies and conjugates
AU2006211037B2 (en) 2005-02-07 2012-05-24 Roche Glycart Ag Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP3770174A1 (en) 2005-10-11 2021-01-27 Amgen Research (Munich) GmbH Compositions comprising cross-species-specific antibodies and uses thereof
EP1957531B1 (en) 2005-11-07 2016-04-13 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
US20070237764A1 (en) 2005-12-02 2007-10-11 Genentech, Inc. Binding polypeptides with restricted diversity sequences
JP5474531B2 (en) 2006-03-24 2014-04-16 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Engineered heterodimeric protein domains
JP2009536527A (en) 2006-05-09 2009-10-15 ジェネンテック・インコーポレーテッド Binding polypeptide with optimized scaffold
EP2035456A1 (en) 2006-06-22 2009-03-18 Novo Nordisk A/S Production of bispecific antibodies
US20080044455A1 (en) 2006-08-21 2008-02-21 Chaim Welczer Tonsillitus Treatment
WO2008027236A2 (en) 2006-08-30 2008-03-06 Genentech, Inc. Multispecific antibodies
ZA200902161B (en) 2006-10-27 2010-06-30 Genentech Inc Antiobodies and immunoconjugates and uses therefor
RU2639543C9 (en) 2006-10-27 2018-06-14 Дженентек, Инк. Antibodies and immunoconjugates and their applications
WO2008119567A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific cd3-epsilon binding domain
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
AR070047A1 (en) 2007-12-27 2010-03-10 Infinity Pharmaceuticals Inc THERAPEUTIC TREATMENTS AGAINST CANCER. COMPOSITION THAT INCLUDES A HEDGEHOG INHIBITOR.
HUE028536T2 (en) 2008-01-07 2016-12-28 Amgen Inc Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
JP2011512125A (en) 2008-02-01 2011-04-21 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Microfluidic image cytometry
IT1391619B1 (en) 2008-11-04 2012-01-11 Silicon Biosystems Spa METHOD FOR THE IDENTIFICATION, SELECTION AND ANALYSIS OF TUMOR CELLS
MX2011004748A (en) 2008-11-20 2011-05-25 Genentech Inc Therapeutic protein formulations.
RU2598248C2 (en) 2009-04-02 2016-09-20 Роше Гликарт Аг Polyspecific antibodies containing antibody of full length and one-chain fragments fab
PL2417156T3 (en) 2009-04-07 2015-07-31 Roche Glycart Ag Trivalent, bispecific antibodies
EP2424567B1 (en) 2009-04-27 2018-11-21 OncoMed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
CA2761233A1 (en) 2009-05-27 2010-12-02 F. Hoffmann-La Roche Ag Tri- or tetraspecific antibodies
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
ES2627909T3 (en) 2009-07-15 2017-08-01 Diatech Holdings, Inc. Drug selection for the treatment of gastric cancer using antibody-based matrices
CA2781519A1 (en) 2009-09-16 2011-03-24 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
US9034658B2 (en) 2009-11-23 2015-05-19 The General Hospital Corporation Microfluidic devices for the capture of biological sample components
ME02505B (en) 2009-12-29 2017-02-20 Aptevo Res & Development Llc Heterodimer binding proteins and uses thereof
WO2011115892A1 (en) 2010-03-15 2011-09-22 Griffin Patrick R Modulators of the retinoic acid receptor-related orphan receptors
AU2011237669B2 (en) 2010-04-06 2016-09-08 Caris Life Sciences Switzerland Holdings Gmbh Circulating biomarkers for disease
JP6022444B2 (en) 2010-05-14 2016-11-09 ライナット ニューロサイエンス コーポレイション Heterodimeric protein and method for producing and purifying it
EP2577310B1 (en) 2010-06-03 2018-11-14 F.Hoffmann-La Roche Ag Immuno-pet imaging of antibodies and immunoconjugates and uses therefor
RU2626537C2 (en) 2010-06-08 2017-07-28 Дженентек, Инк. Antibodies with cysteine substituitions and their conjugates produced by gene engineering
CN101943703A (en) 2010-06-28 2011-01-12 首都医科大学 Nanotechnology-based trace protein detection method
RS59589B1 (en) 2010-11-05 2019-12-31 Zymeworks Inc Stable heterodimeric antibody design with mutations in the fc domain
HUE041335T2 (en) 2011-03-29 2019-05-28 Roche Glycart Ag Antibody fc variants
MX2013011706A (en) * 2011-04-07 2014-04-25 Amgen Inc Novel egfr binding proteins.
EP2748202B1 (en) 2011-08-23 2018-07-04 Roche Glycart AG Bispecific antigen binding molecules
EP2747781B1 (en) 2011-08-23 2017-11-15 Roche Glycart AG Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
PE20141521A1 (en) 2011-08-23 2014-10-25 Roche Glycart Ag T-CELL ACTIVATING ANTIGEN-BINDING BI-SPECIFIC MOLECULES
US20130143237A1 (en) 2011-11-29 2013-06-06 Genentech, Inc. Compositions and methods for prostate cancer analysis
CN102492772A (en) 2011-12-02 2012-06-13 中国人民解放军军事医学科学院放射与辐射医学研究所 Molecule detection signal amplification technique
EP2788752B1 (en) 2011-12-05 2018-10-03 Pierian Holdings, Inc. Method of therapy selection for patients with lung cancer
SI2794905T1 (en) 2011-12-20 2020-08-31 Medimmune, Llc Modified polypeptides for bispecific antibody scaffolds
RU2646498C2 (en) 2012-01-24 2018-03-05 Пфайзер Инк. Methods of detecting 5t4-positive circulating tumor cells and methods of diagnostics of 5t4-positive cancer in mammals
ES2676031T3 (en) 2012-02-15 2018-07-16 F. Hoffmann-La Roche Ag Affinity chromatography based on the Fc receptor
AU2013249985B2 (en) 2012-04-20 2017-11-23 Merus N.V. Methods and means for the production of Ig-like molecules
CN103792364B (en) 2012-10-31 2016-06-08 张宝弘 For detecting reagent and the application thereof of circulating tumor cell ROR1 albumen in peripheral blood
WO2014165818A2 (en) 2013-04-05 2014-10-09 T Cell Therapeutics, Inc. Compositions and methods for preventing and treating prostate cancer
EP2883962B1 (en) 2013-12-16 2017-09-13 Humanitas Mirasole S.p.A. High levels of EMT-TFs for the diagnosis of cancer, in particular of colorectal (CRC) and pancreatic (PC) cancer
BR112016011027A2 (en) 2013-12-20 2017-12-05 Genentech Inc method of producing an antibody, antibodies, pharmaceutical composition, polynucleotide, vector, host cell, method of treating asthma and method of treating a disorder
CA2935393A1 (en) 2014-01-24 2015-07-30 Genentech, Inc. Methods of using anti-steap1 antibodies and immunoconjugates
BR112016022385A2 (en) * 2014-03-28 2018-06-19 Xencor, Inc specific antibodies that bind to cd38 and cd3
UA117289C2 (en) 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Multispecific antibodies
ES2755406T3 (en) 2014-04-17 2020-04-22 Siemens Healthcare Diagnostics Inc Method to avoid false positives in a circulating tumor cell assay
JP6744292B2 (en) 2014-07-29 2020-08-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Multispecific antibody
PL3177643T3 (en) 2014-08-04 2019-09-30 F.Hoffmann-La Roche Ag Bispecific t cell activating antigen binding molecules
KR20170052600A (en) 2014-09-12 2017-05-12 제넨테크, 인크. Cysteine engineered antibodies and conjugates
KR102668727B1 (en) 2015-04-24 2024-05-28 제넨테크, 인크. Multispecific antigen-binding protein
US10017577B2 (en) * 2015-06-15 2018-07-10 Genentech, Inc. Antibodies and immunoconjugates

Also Published As

Publication number Publication date
CA3055132A1 (en) 2018-10-11
EP3606963B1 (en) 2023-08-30
PE20200010A1 (en) 2020-01-06
WO2018184966A1 (en) 2018-10-11
MX2019011769A (en) 2019-11-07
ES2955852T3 (en) 2023-12-07
JP7247101B2 (en) 2023-03-28
CN110494452A (en) 2019-11-22
US11180571B2 (en) 2021-11-23
EP3606963C0 (en) 2023-08-30
RU2019134462A3 (en) 2021-07-13
EP3606963A1 (en) 2020-02-12
CR20190430A (en) 2019-11-01
CN110494452B (en) 2023-08-25
KR20190136054A (en) 2019-12-09
US20200190212A1 (en) 2020-06-18
KR102667951B1 (en) 2024-05-22
AU2018247767A1 (en) 2019-09-19
CL2019002735A1 (en) 2020-01-17
JP2020515277A (en) 2020-05-28
CO2019010164A2 (en) 2019-10-21
PH12019502274A1 (en) 2020-12-07
US11685790B2 (en) 2023-06-27
IL269394A (en) 2019-11-28
BR112019018767A2 (en) 2020-05-05
MA49289A (en) 2020-02-12
RU2019134462A (en) 2021-05-05
US20240279355A1 (en) 2024-08-22
US20220041747A1 (en) 2022-02-10

Similar Documents

Publication Publication Date Title
SG11201908796XA (en) Improved antigen binding receptors
SG11201909154SA (en) Bispecific antibodies specifically binding to pd1 and lag3
SG11201908787WA (en) Novel bispecific antigen binding molecules capable of specific binding to cd40 and to fap
SG11201908784TA (en) Improved antigen binding receptor formats
SG11201909205YA (en) Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15
SG11201810076WA (en) Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
SG11201909218RA (en) Antibodies binding to steap-1
SG11201909344SA (en) Anti-lag3 antibodies
SG11201908088RA (en) Antibodies against pd-l1
SG11201811003PA (en) Anti-pd-l1 antibodies and uses thereof
SG11201804178YA (en) Pd1 and/or lag3 binders
SG11201907753TA (en) Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
SG11201907580SA (en) Combination therapies for treatment of bcma-related cancers and autoimmune disorders
SG11201908527SA (en) High affinity mage-a1-specific tcrs and uses thereof
SG11201908675PA (en) Computer-implemented system and method for performing transaction mixing on a blockchain
SG11201903882VA (en) Il-2 variants for the treatment of autoimmune diseases
SG11201808797XA (en) T cell receptors
SG11201906660TA (en) Anti-tgf-beta antibodies and their use
SG11201803956UA (en) Anti-dr5 antibodies and methods of use thereof
SG11201900772YA (en) Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors
SG11201908847TA (en) Apparatuses, systems and methods for imaging flow cytometry
SG11201908238SA (en) Anti-c5 antibodies and uses thereof
SG11201908127WA (en) Method for producing multispecific antibodies
SG11201908325PA (en) Process for the preparation of glucuronide drug-linkers and intermediates thereof
SG11201907671XA (en) Systems and methods for cracking hydrocarbon streams such as crude oils utilizing catalysts which include zeolite mixtures